PASG News and Press, Passage Bio Inc. From 07/28/22

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:3...

PHILADELPHIA, July 21, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Pa...

PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Michael Kamarck, Ph.D., to its board of ...

PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage Bio, will pa...

Clinical-stage genetic medicines company, Passage Bio (NASDAQ:PASG) announced on Wednesday that the FDA cleared its Investigational New Drug (IND) application for PBML04, a gene therapy candidate targeted Metachromatic Leukodystrophy (MLD). MLD is a fatal lysosomal storage disease affecting c...

• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous s...

Passage Bio (NASDAQ:PASG) notifies that the board and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and CEO and a member of the board, effective immediately. The board has appointed Edgar B. "Chip" Cale, the current general counsel and corporate se...

Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as interim chief executive office...

Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregivers Interim safety data at 13 and seven months from patients in Cohort 1 of the Imagine-1 clinical trial showed low dose of PBGM01 was well toler...

Passage Bio, Inc. (PASG) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Stuart Henderson - Vice President of Corporate Development and Investor Relations Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - Ch...